Hiyama E, Hiyama K, Ohtsu K, Yamaoka H, Fukuba I, Matsuura Y, Yokoyama T
Department of General Medicine, Hiroshima University School of Medicine, Japan.
Med Pediatr Oncol. 2001 Jan;36(1):67-74. doi: 10.1002/1096-911X(20010101)36:1<67::AID-MPO1017>3.0.CO;2-S.
Neuroblastoma shows remarkable heterogeneity, resulting in favorable and unfavorable outcomes. It is well known that almost all cases with MYCN amplification have a poor prognosis. We have previously reported that unfavorable tumors show high telomerase activity, whereas favorable tumors show low or nil activity. We also found that the unfavorable neuroblastoma often have a loss of heterozygosity (LOH) at the MYCL locus.
To clarify the biological and clinical profiles of tumors with genetic abnormalities of the short arm of chromosome 1, we performed deletion mapping on 1p on 92 neuroblastoma tissues and corresponding noncancerous samples obtained from 92 cases for 24 micro- or minisatellite loci.
LOH was detected in at least one locus of 1p in 43 (47%) cases. All samples were classified into four groups according to the deleted pattern: interstitial deletion (group I, n = 20), short terminal deletion (group ST, n = 6), large terminal deletion (group LT, n = 17), and without detectable deletion (group N, n = 49). All group I cases, whose SRO (shortest region of overlap) was at 1p36.1-2, survived disease free, and none of them showed MYCN amplification or high telomerase activity except for one case. On the other hand, in group LT cases, who showed a large terminal deletion from D1S162 (1p32-pter), including the SRO of group 1, only 5 out of 17 have survived disease free, and 13 showed MYCN amplification or high telomerase activity. The six group ST cases showed small terminal deletion from 1p36.3 with modest prognosis, similar to the group N.
Thus, we propose three loci, 1p36.1-2, 1p32-34, and 1p36.3, as the candidate loci of neuroblastoma suppressor genes on chromosome 1p responsible for groups I, LT, and ST, respectively. Among them, the 1p32-34 locus may be associated with aggressiveness of tumor progression, possibly due to MYCN amplification and/or telomerase reactivation, while the remaining two loci may not.
神经母细胞瘤具有显著的异质性,导致预后有好有坏。众所周知,几乎所有MYCN基因扩增的病例预后都很差。我们之前报道过,预后不良的肿瘤显示出高端粒酶活性,而预后良好的肿瘤显示出低活性或无活性。我们还发现,预后不良的神经母细胞瘤在MYCL基因座常出现杂合性缺失(LOH)。
为了阐明1号染色体短臂存在基因异常的肿瘤的生物学和临床特征,我们对92例神经母细胞瘤组织及从92例患者获取的相应非癌样本中的1p进行了24个微卫星或小卫星位点的缺失定位。
43例(47%)病例在1p的至少一个位点检测到LOH。根据缺失模式将所有样本分为四组:中间缺失(I组,n = 20)、短末端缺失(ST组,n = 6)、长末端缺失(LT组,n = 17)以及未检测到缺失(N组,n = 49)。I组所有病例的最短重叠区域(SRO)位于1p36.1 - 2,均无病存活,除1例病例外,均未显示MYCN基因扩增或高端粒酶活性。另一方面,LT组病例显示从D1S162(1p32 - pter)开始的长末端缺失,包括I组的SRO区域,17例中只有5例无病存活,13例显示MYCN基因扩增或高端粒酶活性。6例ST组病例显示从1p36.3开始的小末端缺失,预后中等,与N组相似。
因此,我们提出三个位点,即1p36.1 - 2、1p32 - 34和1p36.3,分别作为1号染色体上神经母细胞瘤抑制基因的候选位点,分别对应I组、LT组和ST组。其中,1p32 - 34位点可能与肿瘤进展的侵袭性相关,可能是由于MYCN基因扩增和/或端粒酶重新激活,而其余两个位点可能并非如此。